--- title: "Guotai Bio-medicine ETF (512290) rose over 1%, with the focus on innovative drugs going overseas and value realization becoming the core highlight" type: "News" locale: "en" url: "https://longbridge.com/en/news/282678334.md" description: "Guotai CSI Bio-medicine ETF (512290) rose over 1% on April 14, with the focus on innovative drugs going overseas and value realization becoming the market highlight. Xiangcai Securities pointed out that the 2025 global pharmaceutical sales TOP 100 list shows that the industry landscape is undergoing profound changes, with market growth momentum shifting from tumor immunity to chronic diseases such as metabolic disorders, particularly the rise of GLP-1 drugs. Technological iteration has spawned new growth poles, and innovative therapies have become the new engine of growth. This ETF tracks the CSI Bio-medicine Index, reflecting the overall performance of listed companies in the biopharmaceutical sector. Risk warning: Individual stock analysis does not constitute investment advice; investment should be approached with caution" datetime: "2026-04-14T10:53:12.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282678334.md) - [en](https://longbridge.com/en/news/282678334.md) - [zh-HK](https://longbridge.com/zh-HK/news/282678334.md) --- # Guotai Bio-medicine ETF (512290) rose over 1%, with the focus on innovative drugs going overseas and value realization becoming the core highlight On April 14th, the Guotai Bio-medicine ETF (512290) rose over 1%, with the focus shifting to the overseas expansion of innovative drugs and value realization. Xiangcai Securities pointed out that the 2025 global pharmaceutical sales TOP 100 list shows that the industry landscape is undergoing profound changes, with market growth momentum shifting from tumor immunotherapy to chronic diseases such as metabolic disorders. The rise of GLP-1 drugs is particularly noteworthy. Technological iterations have spawned new growth poles, with innovative therapies becoming new engines of growth. ADC drugs continue to see increased volume, while emerging therapies such as nuclear medicine, small nucleic acids, and bispecific antibodies have entered the list for the first time and achieved rapid growth. Currently, the overseas expansion of innovative drugs and value realization have become core focuses, and the deep integration of AI and biomedicine is transitioning from concept to industrialization. The Guotai Bio-medicine ETF (512290) tracks the CSI Biomedicine Index (930726), which selects listed company securities involved in cell therapy, gene sequencing, blood products, biopharmaceuticals, vaccines, and in vitro diagnostics from the Shanghai and Shenzhen markets as index samples to reflect the overall performance of related listed company securities in the biomedicine field. This index emphasizes technological innovation in the pharmaceutical and healthcare industry, with constituent stocks exhibiting high growth potential and technological attributes, focusing on the development trends of the biomedicine industry. Daily Economic News ### Related Stocks - [161726.CN](https://longbridge.com/en/quote/161726.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [160635.CN](https://longbridge.com/en/quote/160635.CN.md) - [600095.CN](https://longbridge.com/en/quote/600095.CN.md) ## Related News & Research - [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md) - [VanEck, Grayscale file fresh BNB ETF amendments as race for next altcoin spot ETF accelerates](https://longbridge.com/en/news/286652991.md) - [$100 Invested In iShares S&P 500 Growth ETF 20 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/286800978.md) - [New Core Equity ETF Drops As Low-Cost Active Funds Become Wall Street's New Obsession](https://longbridge.com/en/news/287253853.md) - [$1000 Invested In Vanguard S&P 500 Growth ETF 15 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/286797286.md)